Clinical trials: Prostatic Diseases
- Condition Prostatic Diseases
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer, Osteoporosis
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
- Trial name
- NCT01025479
- Where
- 18 sites in South Korea
- Volunteers
- 829 people
- Sponsor
- AstraZeneca
Prostatic Hyperplasia
Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice
- Trial name
- NCT02244346
- Testing
- Secotex®
- Volunteers
- 811 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers.
- Trial name
- NCT02244307
- Testing
- alpha-adrenergic blocker
- Volunteers
- 4,561 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Hyperplasia
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom…
- Trial name
- NCT02244320
- Testing
- Tamsulosin
- Volunteers
- 4,150 people
- Sponsor
- Boehringer Ingelheim
Prostatic Neoplasms
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Primary Objective: Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: Describe treatment patterns Describe the characteristics and outcomes of patients…
- Trial name
- PORTREAT (NCT01076751)
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for…
- Trial name
- UPWARD (NCT01977651)
- Testing
- Enzalutamide
- Where
- 76 sites in United States, Argentina and 18 more
- Volunteers
- 424 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Prostate Cancer
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone density, changes in blood…
- Trial name
- NCT01234350
- Where
- 160 sites in Belgium, Denmark and 13 more
- Volunteers
- 1,493 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Prostate Cancer
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
- Trial name
- PULSE (NCT07484269)
- Where
- Switzerland
- Volunteers
- 753 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia
This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1).
- Trial name
- NCT00593593
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel
This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to…
- Trial name
- NCT05735652
- Testing
- SpaceOAR Hydrogel
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.
- Trial name
- APEX (NCT06560476)
- Testing
- Data collection
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Urotronic Inc.
Prostate Cancer
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy).
- Trial name
- VAPOR-LTR (NCT07455058)
- Testing
- Vanquish Therapy
- Where
- 4 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Francis Medical Inc.
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.
- Trial name
- NCT03209492
- Testing
- Leuprorelin acetate
- Where
- Japan
- Volunteers
- 333 people
- Sponsor
- Takeda
Benign Prostatic Hyperplasia
GreenLight XPS Laser System Retrospective Chart Review
The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.
- Trial name
- NCT02139969
- Testing
- GreenLight XPS Laser System
- Where
- 6 sites in United States, Canada
- Volunteers
- 956 people
- Sponsor
- Boston Scientific Corporation